Next Article in Journal
Epigenomics of Plant Responses to Environmental Stress
Previous Article in Journal
From Flies to Mice: The Emerging Role of Non-Canonical PRC1 Members in Mammalian Development
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle
Epigenomes 2018, 2(1), 5; https://doi.org/10.3390/epigenomes2010005

Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells

1
Department of Biochemistry and Genetics, University of Navarra School of Sciences, 31008 Pamplona, Spain
2
Molecular Pathology Research Unit, Virgen de la Salud Hospital, 45005 Toledo, Spain
3
IdiPaz Research Unit, La Paz University Hospital, 28046 Madrid, Spain
4
Department of Pathology, University of Navarra Clinic, 31008 Pamplona, Spain
*
Author to whom correspondence should be addressed.
Received: 30 December 2017 / Revised: 6 February 2018 / Accepted: 13 February 2018 / Published: 19 February 2018
Full-Text   |   PDF [1612 KB, uploaded 23 February 2018]   |  

Abstract

Glioblastoma is the most common form of glioma, as well as the most aggressive. Patients suffering from this disease have a very poor prognosis. Surgery, radiotherapy, and temozolomide are the only approved treatments nowadays. Panobinostat is a pan-inhibitor of histone deacetylases (HDACs) that has been shown to break some pathways which play an important role in cancer development. A global intention of using panobinostat as a therapeutic agent against glioblastoma is beginning to be a reality. We have treated the LN405 glioblastoma cell line with temozolomide, panobinostat, and combined treatment, in order to test apoptosis, colony formation, and a possible molecular reversion of the mesenchymal phenotype of the cells to an epithelial one. Our results show that panobinostat decreased N-cadherin levels in the LN405 glioblastoma cell line while it increased the expression of E-cadherin, which might be associated with a mesenchymal–epithelial transition in glioblastoma cells. Colony formation was reduced, and apoptosis was increased with treatments. Our research highlights the importance of panobinostat as a potential adjuvant therapy to be used with temozolomide to treat glioblastoma and the advantages of the combined treatment versus temozolomide alone, which is currently the first-line treatment used to treat this tumor. View Full-Text
Keywords: panobinostat; temozolomide; glioblastoma; epithelial-mesenchymal transition panobinostat; temozolomide; glioblastoma; epithelial-mesenchymal transition
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Urdiciain, A.; Meléndez, B.; Rey, J.A.; Idoate, M.A.; Castresana, J.S. Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells. Epigenomes 2018, 2, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Epigenomes EISSN 2075-4655 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top